NF-κB activation and inhibition: A review

Shock

Volumn 18, Issue 2, 2002, Pages 99-106

  Sun, Zhengwu ^a   Andersson, Roland ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Activation; Inhibitor; Nuclear factor kappa

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL; CRITICAL ILLNESS; DRUG ANTAGONISM; GENETICS; HOSPITALIZATION; HUMAN; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY; SHOCK; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION;

ANIMALS; CRITICAL ILLNESS; HUMANS; MICE; MICE, KNOCKOUT; NF-KAPPA B; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SHOCK; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); UP-REGULATION;

EID: 0036689830     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200208000-00001     Document Type: Review

References (64)

1. Mercurio F, Manning AM: Multiple signals converging on NF-κB. Curr Opin Cell Biol 11:226-232, 1999.
2. Baldwin ASJ: The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14:649-683, 1996.
3. Ghosh S, May MJ, Kopp EB: NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260, 1998.
4. May MJ, Ghosh S: Signal transduction through NF-κB. Immunol Today 19: 80-88, 1998.
5. Whiteside ST, Israel A: IκB proteins: structure, function and regulation. Semin Cancer Biol 8:75-82, 1997.
6. Henkel T, Zabel U, van Zee K, et al.: Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-κB subunit. Cell 68:1121-1133, 1992.
7. Abraham E: NF-κB activation. Crit Care Med 28:N100-N104, 2000.
8. Baeuerle PA, Baltimore D: NF-κB: ten years after. Cell 87:13-20, 1996.
9. Franzoso G, Carlson L, Scharton-Kersten T, et al.: Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity 6:479-490, 1997.
10. Lenardo M, Siebenlist U: Bcl-3-mediated nuclear regulation of the NF-κB trans-activating factor. Immunol Today 15:145-147, 1994.
11. Bohuslav J, Kravchenko VV, Parry GC, et al.: Regulation of an essential innate immune response by the p50 subunit of NF-κB. J Clin Invest 102:1645-1652, 1998.
12. Tran K, Merika M, Thanos D: Distinct functional properties of IκBα and IκBβ. Mol Cell Biol 17:5386-5399, 1997.
13. Zandi E, Rothwarf DM, Delhase M, et al.: The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKκ, necessary for IκB phosphorylation and NF-κB activation. Cell 91:243-252, 1997.
14. Yaron A, Gonen H, Alkalay I, et al.: Inhibition of NF-κB cellular function via specific targeting of the I-κB-ubiquitin ligase. EMBO J 16:6486-6494, 1997.
15. McKinsey TA, Chu ZL, Ballard DW: Phosphorylation of the PEST domain of IκBβ regulates the function of NF-κB/IκBβ complexes. J Biol Chem 272: 22377-22380, 1997.
16. Weil R, Laurent-Winter C, Israel A: Regulation of IκBβ degradation: similarities to and differences from IκBα. J Biol Chem 272:9942-9949, 1997.
17. Arenzana-Seisdedos F, Turpin P, Rodriguez M, et al.: Nuclear localization of IκBα promotes active transport of NF-κB from the nucleus to the cytoplasm. J Cell Sci 110:369-378, 1997.
18. Moine P, Shenkar R, Kaneko D, et al.: Systemic blood loss affects NF-κB regulatory mechanisms in the lungs. Am J Physiol 273:L185-L192, 1997.
19. Adcock IM, Newton R, Barnes PJ: NF-κB involvement in IL-1β induction of GM-CSF and COX-2: inhibition by glucocorticoids does not require I-κB. Biochem Soc Trans 25:1545, 1997.
20. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 12:2005-2015, 1993.
21. Blackwell TS, Debelak JP, Venkatakrishnan A, et al.: Acute lung injury after hepatic cryoablation: correlation with NF-κB activation and cytokine production. Surgery 126:518-526, 1999.
22. Shenkar R, Abraham E: Mechanisms of lung neutrophil activation after hemorrhage or endotoxemia: roles of reactive oxygen intermediates, NF-κB, and cyclic AMP response element binding protein. J Immunol 163:954-962, 1999.
23. Le Tulzo Y, Shenkar R, Kaneko D, et al.: Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-κB regulation and cytokine expression. J Clin Invest 99:1516-1524, 1997.
24. Serkkola E, Hurme M: Activation of NF-κB by cAMP in human myeloid cells. FEBS Lett 334:327-330, 1993.
25. 2+ in oxidant-induced NF-κB activation. FEBS Lett 385:58-62, 1996.
26. Zhong H, Voll RE, Ghosh S: Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1:661-671, 1998.
27. Jap TS, Wu YC, Chiou JY, Kwok CF: A novel mutation in the hepatocyte nuclear factor-1 alpha/MODY3 gene in Chinese subjects with early-onset type 2 diabetes mellitus in Taiwan. Diabet Med 17:390-393, 2000.
28. Janknecht R, Hunter T: Transcription: a growing coactivator network. Nature 383:22-23, 1996.
29. Parker D, Rivera M, Zor T, et al.: Role of secondary structure in discrimination between constitutive and inducible activators. Mol Cell Biol 19:5601-5607, 1999.
30. Ollivier V, Parry GCN, Cobb RR, et al.: Elevated cyclic AMP inhibits NF-κB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 271:20828-20835, 1996.
31. Parry GC, Mackman N: Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-κB-mediated transcription. J Immunol 159: 5450-5456, 1997.
32. Woronicz JD, Gao X, Cao Z, et al.: IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 278:866-869, 1997.
33. Chen F, Castranova V, Shi X, Demers LM: New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45:7-17, 1999.
34. Malinin NL, Boldin MP, Kovalenko AV, Wallach D: MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385:540-544, 1997.
35. Nakano H, Shindo M, Sakon S, et al.: Differential regulation of IκB kinase α and β by two upstream kinases, NF-κB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA 95:3537-3542, 1998.
36. Nemoto S, DiDonato JA, Lin A: Coordinate regulation of IκB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-κB-inducing kinase. Mol Cell Biol 18:7336-7343, 1998.
37. Mercurio F, Murray BW, Shevchenko A, et al.: IκB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex. Mol Cell Biol 19:1526-1538, 1999.
38. O'Connell MA, Bennett BL, Mercurio F, et al.: Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells. J Biol Chem 273: 30410-30414, 1998.
39. Yamaoka S, Courtois G, Bessia C, et al.: Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93:1231-1240, 1998.
40. Scherer DC, Brockman JA, Chen Z, et al.: Signal-induced degradation of IκB α requires site-specific ubiquitination. Proc Natl Acad Sci USA 92:11259-11263, 1995.
41. Barnes PJ: Nuclear factor-κB. Int J Biochem Cell Biol 29:867-870, 1997.
42. Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18:6853-6866, 1999.
43. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr: Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor κB DNA binding. J Biol Chem 274:31868-31874, 1999.
44. Rossi A, Kapahi P, Natoli G, et al.: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403:103-108, 2000.
45. Barkett M, Gilmore TD: Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18:6910-6924, 1999.
46. Rayet B, Gelinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938-6947, 1999.
47. Foo SY, Nolan GP: NF-κB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet 15:229-235, 1999.
48. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000.
49. Kasibhatla S, Brunner T, Genestier L, et al.: DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol Cell 1:543-551, 1998.
50. Levkau B, Scatena M, Giachelli CM, et al.: Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-κB loop. Nat Cell Biol 1: 227-233, 1999.
51. Ryan KM, Ernst MK, Rice NR, Vousden KH: Role of NF-κB in p53-mediated programmed cell death. Nature 404:892-897, 2000.
52. Guttridge DC, Albanese C, Reuther JY, et al.: NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785-5799, 1999.
53. Krappmann D, Emmerich F, Kordes U, et al.: Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18: 943-953, 1999.
54. Jo H, Zhang R, Zhang H, et al.: NF-κB is required for H-ras oncogene-induced abnormal cell proliferation and tumorigenesis. Oncogene 19:841-849, 2000.
55. George CL, Fantuzzi G, Bursten S, et al.: Effects of lisofylline on hyperoxia-induced lung injury. Am J Physiol 276:L776-L785, 1999.
56. Wang XC, Saban R, Kaysen JH, et al.: Nuclear factor-κB mediates lipopolysaccharide-induced inflammation in the urinary bladder. J Urol 163:993-998, 2000.
57. Parsey MV, Kaneko D, Shenkar R, Abraham E: Neutrophil apoptosis in the lung after hemorrhage or endotoxemia: apoptosis and migration are independent of IL-1β. Clin Immunol 91:219-225, 1999.
58. Schwartz MD, Moore EE, Moore FA, et al.: Nuclear factor-κ B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 24:1285-1292, 1996.
59. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 5:412-417, 1999.
60. Epinat JC, Gilmore TD: Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene 18:6896-6909, 1999.
61. Bondeson J, Foxwell B, Brennan F, Feldmann M: Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA 96:5668-5673, 1999.
62. Morikawa M, Shorthouse RA, Suto MJ, et al.: A novel inhibitor of nuclear factor-κB and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivo. Transplant Proc 29:1269-1270, 1997.
63. Wong HK, Kammer GM, Dennis G, Tsokos GC: Abnormal NF-κB activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol 163:1682-1689, 1999.
64. Lee SJ, Dimtchev A, Lavin MF, et al.: A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κB. Oncogene 17: 1821-1826, 1998.